On Aug. 3, 2020, Atossa Therapeutics announced that it had received approval from the ethics committee to open a Phase 1 clinical study in Australia using Atossaﾒs proprietary drug candidate AT-301, to be administered by nasal spray. All necessary approvals had now been obtained and enrollment is expected to begin in the next 30 days.